iCumulus is a new-age global fulfilment platform, leading the revolution of e-commerce, turning it into a totally shared & unified global economy. iCumulus connects your business to a network of global logistics providers, creating a unique shared ecosystem with the most competitive shipping rates. Unlike traditional logistics providers, iCumulus scales not by assets, staff or inventory, but by connecting true demand to supply ensuring best consumer experience. Our comprehensive cloud based e-fulfilment platform manages all distributions, purchasing, into store and consumer deliveries at no additional cost. We want our customers to be free to deal with what's important to them - service their customers, allowing them grow sales and reach new markets.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

TAKEDA TO ACQUIRE ADAPTATE BIOTHERAPEUTICS TO DEVELOP NOVEL GAMMA DELTA (ΓΔ) T CELL ENGAGER THERAPIES TARGETING SOLID TUMORS

Takeda | January 11, 2022

news image

Takeda Pharmaceutical Company Limited announced the exercise of its option to acquire Adaptate Biotherapeutics a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells. Through the acquisition, Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programs. Adaptate’s γδ T cell engagers are des...

Read More

MEDICAL

MATICA BIO LAUNCHES MATIMAX™ CELL LINES AT BIO INTERNATIONAL CONVENTION

Businesswire | June 07, 2023

news image

Matica Biotechnology, Inc. a contract development and manufacturing organization specializing in the GMP production of cell and gene therapies, today unveiled the company’s new MatiMax™ cell lines at the BIO International Convention, taking place in Boston, MA.. Proprietary to Matica Bio, MatiMaxTM HEK293 and HEK293T cell lines have been rigorously optimized to enable. Faster doubling times – Reaching as low as 17 hours, which can significan...

Read More

INDUSTRIAL IMPACT, MEDICAL

IOVANCE BIOTHERAPEUTICS COMPLETES BIOLOGICS LICENSE APPLICATION (BLA) SUBMISSION FOR LIFILEUCEL IN ADVANCED MELANOMA

Globenewswire | March 27, 2023

news image

Iovance Biotherapeutics, Inc. a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced it has completed its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for lifileucel. Lifileucel is a tumor infiltrating lymphocyte (TIL) therapy intended as a treatment for patients with advanced melanoma who progressed on or after prior anti-PD-1/L1 therapy and targeted therapy, where applicable. There are no...

Read More

INDUSTRIAL IMPACT

NAVERIS INC. RAISES $51 MILLION TO ADVANCE COMMERCIALIZATION OF NAVDX

Naveris, Inc. | September 20, 2022

news image

Naveris, Inc., a commercial-stage life sciences company dedicated to improving patient care through earlier detection of viral-driven cancers, today announced a $33.4 million expansion of its Series A financing, bringing the total investment in Naveris to $51 million. The financing was led by Gurnet Point Capital, joined by TechU Ventures and BrightEdge, the impact and venture capital arm of the American Cancer Society. Naveris’ blood tests for earlier cancer detection use p...

Read More
news image

CELL AND GENE THERAPY

TAKEDA TO ACQUIRE ADAPTATE BIOTHERAPEUTICS TO DEVELOP NOVEL GAMMA DELTA (ΓΔ) T CELL ENGAGER THERAPIES TARGETING SOLID TUMORS

Takeda | January 11, 2022

Takeda Pharmaceutical Company Limited announced the exercise of its option to acquire Adaptate Biotherapeutics a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells. Through the acquisition, Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programs. Adaptate’s γδ T cell engagers are des...

Read More
news image

MEDICAL

MATICA BIO LAUNCHES MATIMAX™ CELL LINES AT BIO INTERNATIONAL CONVENTION

Businesswire | June 07, 2023

Matica Biotechnology, Inc. a contract development and manufacturing organization specializing in the GMP production of cell and gene therapies, today unveiled the company’s new MatiMax™ cell lines at the BIO International Convention, taking place in Boston, MA.. Proprietary to Matica Bio, MatiMaxTM HEK293 and HEK293T cell lines have been rigorously optimized to enable. Faster doubling times – Reaching as low as 17 hours, which can significan...

Read More
news image

INDUSTRIAL IMPACT, MEDICAL

IOVANCE BIOTHERAPEUTICS COMPLETES BIOLOGICS LICENSE APPLICATION (BLA) SUBMISSION FOR LIFILEUCEL IN ADVANCED MELANOMA

Globenewswire | March 27, 2023

Iovance Biotherapeutics, Inc. a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced it has completed its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for lifileucel. Lifileucel is a tumor infiltrating lymphocyte (TIL) therapy intended as a treatment for patients with advanced melanoma who progressed on or after prior anti-PD-1/L1 therapy and targeted therapy, where applicable. There are no...

Read More
news image

INDUSTRIAL IMPACT

NAVERIS INC. RAISES $51 MILLION TO ADVANCE COMMERCIALIZATION OF NAVDX

Naveris, Inc. | September 20, 2022

Naveris, Inc., a commercial-stage life sciences company dedicated to improving patient care through earlier detection of viral-driven cancers, today announced a $33.4 million expansion of its Series A financing, bringing the total investment in Naveris to $51 million. The financing was led by Gurnet Point Capital, joined by TechU Ventures and BrightEdge, the impact and venture capital arm of the American Cancer Society. Naveris’ blood tests for earlier cancer detection use p...

Read More

Resources

resource image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Single-cell RNA Sequencing and Analysis

Video

resource image

CELL AND GENE THERAPY

Mainstreaming Cell & Gene Therapies

Whitepaper

resource image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Making the Promise of mRNA a Reality: OvercomingScale-Up Challenges

Whitepaper

resource image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Single-cell RNA Sequencing and Analysis

Video

resource image

CELL AND GENE THERAPY

Mainstreaming Cell & Gene Therapies

Whitepaper

resource image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Making the Promise of mRNA a Reality: OvercomingScale-Up Challenges

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us